Business
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals,
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"– Numerous value-driving commercial, regulatory and pipeline milestones anticipated –\nCARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 3pm PT; the presentation is available today on the Ionis website.\n\n \n \n \n \n \n \n\n \nIn 2023, Ionis made significant progress in advancing a steady cadence of medicines for people with serious diseases, including the U.S. approval of WAINUA™ (eplontersen) for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) and the accelerated approval of QALSODY® (tofersen) for SOD-1 amyotrophic lateral sclerosis (ALS). Ionis also shared positive Phase 3 trial readouts for WAINUA and for investigational olezarsen in familial chylomicronemia syndrome (FCS), a rare, life-threatening disease characterized by severely elevated triglycerides; olezarsen is also being evaluated in an ongoing Phase 3 program in severe hypertriglyceridemia. The late-stage pipeline expanded to nine medicines in Phase 3 trials for 11 potential indications and Ionis reported a number of additional positive data readouts. Ionis also continued to make key advances in its industry-leading technology platform, which now includes multiple RNA modalities and gene editing to support the next wave of medicines.\n\"With the recent approval of our first co-commercialized medicine, WAINUA for ATTRv-PN, and the potential for our first independent commercial launch with olezarsen in FCS later this year, Ionis is delivering on our vision to unlock better futures for people with serious diseases by building a leading fully-integrated, science-driven biopharmaceutical company,\" said Brett P. Monia, Ph.D., Ionis' chief executive officer. \"We expect 2024 to be another robust year of execution and achievement, beginning with topline Phase 3 results expected in the first quarter for donidalorsen in hereditary angioedema. Ionis also looks forward to many additional regulatory milestones, important readouts across our mid- and late-stage pipeline and continued technology advances in our leading RNA therapeutics platform.\"\n202...